Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2021 | Autologous macrophages with an anti-HER2 CAR in HER2 overexpressing solid tumors

Chimeric antigen receptor (CAR) T-cell approaches have led to remarkable advances in the treatment of patients with hematologically malignancies but not yet within solid tumors. In this interview, Yara Abdou, MD, University of North Carolina, Chapel Hill, NC, discusses an ongoing first-in-human Phase I study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in patients with HER2-overexpressing solid tumors. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.